目的 探讨强化他汀治疗对急性冠状动脉综合征经皮冠状动脉介入治疗后短期疗效及安全性。方法 从我院2014年5 月至2016年5月收治的急性冠状动脉综合征患者中抽选410例，给予患者经皮冠状动脉介入治疗，并强化患者的降脂 治疗，给予其每日40mg阿托伐他汀口服治疗，观察并比较本组患者治疗前和治疗1个月后的血脂水平变化情况，评 价其临床疗效和安全性。结果 强化他汀治疗1个月后，本组410例患者的TC、TG、LDL-C等临床指标较治疗前均有明 显下降，前后比较有统计学意义，P<0.05；治疗前和治疗后患者的ALT、Cr水平比较差异不大，无统计学意义，P＞ 0.05；本组患者血脂达标率为96.59%；410例患者在治疗期间共有31例患者发生不良反应(7.56%)。结论 强化他汀 治疗对急性冠状动脉综合征经皮冠状动脉介入治疗患者具有良好的疗效，给予患者介入治疗后早期服用大量阿托伐 他汀，能显著降低其血脂水平，且不良反应发生率低，安全有效，值得临床推广。

Objective To investigate short-term efficacy and safety of intensive statin in acute coronary syndrome (ACS) after percutaneous coronary intervention. Methods 410 cases with ACS in our hospital from May 2014 to May 2016 were selected in this study. All of them were treated with percutaneous coronary artery interventional therapy, and intensive lipid-lowering therapy in patients with the daily 40mg, giving atorvastatin oral treatment, treatment of this group of patients before treatment and the changes of blood lipid after 1 month to observe and evaluate the clinical efficacy and safety of intensive statin therapy. Results After 1 month treatment of intensive statin, this group of 410 patients with TC,TG,LDL-C and other clinical indicators before treatment were significantly decreased compared with 1 month before treatment with statistical significance (P<0.05),and the level of Cr had little difference with no statistical significance(P>0.05). The standard rate blood lipid was 96.59%. Side effects were occurred in 21 cases among 410 patients (7.56%). Conclusion Intensive statin therapy in ACS percutaneous coronary intervention in patients with good effect, administered to a patient after taking a lot of early intervention therapy atorvastatin can significantly lower their blood lipid levels, improve liver and kidney function, and low incidence of adverse reactions, is safe and effective, worthy of promotion.